

NOW ENROLLING IN RENAL CELL CARCINOMA




PHASE 3 (NCT03729245)

PIVOT-09: Bempegaldesleukin with nivolumab in patients with advanced renal cell carcinoma (RCC)

A randomized study of bempegaldesleukin (BEMPEG; NKTR-214) in combination with nivolumab (NIVO) compared with the Investigator's choice of tyrosine kinase inhibitor therapy (either sunitinib or cabozantinib) for previously untreated advanced RCC¹

ENROLL NOW

Scan here to find out more about this clinical study at [ClinicalTrials.gov](https://clinicaltrials.gov)



Bempegaldesleukin is an investigational first-in-class CD122-preferential IL-2-pathway agonist²

Nivolumab is a PD-1 blocking antibody³

BEMPEG, bempegaldesleukin (NKTR-214); IL-2, interleukin-2; IMDC, International Metastatic Renal Cell Carcinoma Database Consortium; NIVO, nivolumab; PD-1, programmed death-1; PD-L1, programmed death-ligand 1.

1. ClinicalTrials.gov. NCT03729245. <https://clinicaltrials.gov/ct2/show/NCT03729245>. Accessed September 3, 2020. 2. Charych DH, et al. *Clin Cancer Res* 2016;22:680-690.

3. Opdivo (nivolumab) Prescribing Information (Princeton, NJ: Bristol Myers Squibb; revised: June 2020).

ACTIVE CLINICAL TRIALS WITH BEMPEGALDESLEUKIN AND NIVOLUMAB


NEKTAR

 Bristol Myers Squibb™

Bempegaldesleukin (BEMPEG; NKTR-214) in combination with nivolumab (NIVO) leverage two immuno-oncology pathways with the aim of addressing the unmet needs of patients living with cancer

FIND OUT MORE

Scan here to discover more about BEMPEG at Nektar.com



BEMPEG, bempegaldesleukin (NKTR-214); NIVO, nivolumab.

FOR EDUCATIONAL PURPOSES ONLY.

This compound and the combination of agents and their uses have not been approved.

Nektar Therapeutics, 455 Mission Bay Boulevard, South San Francisco, California 94158. Copyright Nektar Therapeutics © 2020. All rights reserved.